Keywords: oral Wegovy pill, Foundayo orforglipron, GLP-1 pill race, obesity pill sales, Novo Nordisk vs Eli Lilly, semaglutide pill, oral obesity drug market

Key Highlights

  • Novo Nordisk A/S (NYSE:NVO)'s oral Wegovy pill generated approximately USD 494 million in Q2 2026 sales, missing analyst estimates despite a stronger-than-expected debut quarter of about USD 355 million earlier in 2026.
  • Eli Lilly and Company (NYSE:LLY)'s rival oral GLP-1 pill, orforglipron, branded Foundayo, posted USD 98 million in sales in its first full quarter on the market.
  • Novo's CEO has defended the pricing strategy behind the oral pill as a deliberate sweet spot rather than a shortfall, even as the sales trajectory has fallen short of the company's own outlook.
  • The oral pill segment is viewed as a critical new battleground in the obesity drug market because pills are cheaper to manufacture and more convenient for patients than weekly injections.

Two Different Launch Trajectories

The race to dominate the oral GLP-1 obesity pill market has produced two distinct early trajectories. Novo Nordisk A/S 's oral Wegovy pill launched strongly, generating roughly USD 355 million in its debut quarter, but growth decelerated in the following quarter to approximately USD 494 million, below what analysts had modeled. Eli Lilly and Company 's rival pill, orforglipron, now sold under the Brand name Foundayo, entered the market later and posted a smaller USD 98 million in its first full quarter, a smaller base but one management describes as an intentional, controlled ramp while Manufacturing capacity is built out.

Why the Oral Pill Segment Matters So Much

Oral GLP-1 pills are seen as the next major inflection point in the obesity drug market because they are cheaper to manufacture at scale than injectable formulations and remove the need for patients to self-inject weekly, a barrier that has limited uptake among some potential users. Novo Nordisk's CEO has publicly defended the oral pill's pricing as deliberately positioned in what he called a sweet spot intended to balance affordability with margin, arguing that near-term sales softness reflects a considered strategy rather than weak demand. Eli Lilly, meanwhile, has said it is stockpiling inventory of orforglipron specifically to avoid repeating the Supply shortages that hampered its earlier injectable tirzepatide launches.

A Market Still Being Defined

With combined oral pill sales from the two companies still well under a billion dollars per quarter, the category remains in its early innings relative to the tens of billions of dollars in quarterly Revenue generated by injectable GLP-1 drugs like Zepbound, Wegovy, Mounjaro and Ozempic. Analysts are watching whether either company can accelerate prescriber and payer adoption of the oral format enough to meaningfully cannibalize injectable demand, or whether pills instead expand the overall addressable obesity drug market by reaching patients who were unwilling to use injections.

Where Things Stand

The next several quarters will be telling for both companies as manufacturing capacity scales and payer coverage decisions catch up with each oral product. Investors should watch prescription Volume trends and any updated peak sales guidance from both Novo Nordisk and Eli Lilly as the clearest signal of which oral pill strategy is gaining the upper hand.